Author's response to reviews

Title: Predictors and Correlates for Weight Changes in Patients Co-Treated with Olanzapine and Weight Mitigating Agents; a Post-Hoc Analysis

Authors:

Virginia L Stauffer (Stauffer_Virginia@Lilly.com)
Ilya Lipkovich (Lipkovich_Ilya_A@Lilly.com)
Vicki Poole Hoffmann (Hoffmann_Vicki_Poole@Lilly.com)
Alexandra N Heinloth (Alexandra.Heinloth@i3Statprobe.com)
H Scott McGregor (Mcgregor_Scott_H@Lilly.com)
Bruce J Kinon (Kinon_Bruce@Lilly.com)

Version: 4 Date: 6 March 2009

Author's response to reviews: see over
March 6, 2009

Sabina Alam, PhD
Editor, BMC Psychiatry

Dear Dr. Alam:

On behalf of all the authors, thank you very much for the opportunity to resubmit our manuscript, “Predictors and Correlates for Weight Changes in Patients Co-Treated with Olanzapine and Weight Mitigating Agents; a Post-Hoc Analysis”, to BMC Psychiatry.

We appreciate the helpful suggestion of the reviewer and believe that we have responded completely. Please find a detailed response listed below and modifications highlighted in the manuscript.

Please address correspondence to Virginia Stauffer, PharmD, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285; phone: 317-257-3410, FAX: 317-276-7100, E-mail: Stauffer_Virginia@Lilly.com.

Sincerely,

Virginia Stauffer, PharmD
Lilly USA, LLC

Reviewer #1:

These authors have clarified some major questions. Nevertheless, it should be included to the discussion as a limitation of the study that the authors only included patients with a BMI equal or greater 25kg/m2. Thus, results cannot be generalised to all patients, as the authors state themselves in their response. Without mentioning this important detail the last paragraph on page 20 in the discussion is not appropriate and requires change.

Response: To address the concern of the reviewer, we added the following limitation statement to the discussion (p. 19):

“A limitation of the analyses presented here is that only patients with a BMI of ≥25 kg/m² were included, therefore the results cannot be generalized to patients with a BMI of <25 kg/m². Additionally, the enrollment criteria….”